6 news items
Vir Biotechnology's SOLSTICE Data To Be Featured At The European Association For The Study Of The Liver Congress 2024
VIR
21 May 24
on participants that have reached 12 and 24 weeks of chronic suppressive treatment. The Company will also share 48-week treatment data on the efficacy
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
VIR
21 May 24
. The update will include data on participants that have reached 12 and 24 weeks of chronic suppressive treatment. The Company will also share 48-week
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
VIR
13 May 24
of a treatment regimen for people living with chronic HBV infection and chronic hepatitis D virus (HDV) infection. The Breakthrough Therapy
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
trigger a potent and specific immune response in chronic Hepatitis B (CHB) patients and linking that response to improved clinical outcomes
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
VIR
5 Mar 24
the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has
dzghhim35pht2akg8hytv1nxsyerrn353brjqkpikfr4
VIR
22 Feb 24
in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% (6/6) of participants had HDV RNA less than
- Prev
- 1
- Next